Prolaris test accurately predicts the 10-year risk of metastases in men treated for prostate cancer.- Myriad Genetics Inc.

- Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, announced new data demonstrating the utility of the Prolaris test to accurately predict the 10-year risk of metastases in men treated for prostate cancer. The data were presented at the American Urological Association (AUA) 2017 Annual Meeting in Boston, Mass.

This study was conducted in collaboration with Stephen Bardot, M.D., and colleagues at Ochsner Clinic in New Orleans, Louisiana. A total of 767 men with localized prostate cancer were evaluated using the Prolaris test plus CAPRA (i.e., clinical features) to predict the risk of metastatic disease up to 10 years following diagnosis. Approximately 40 percent of the patients in the study were African Americans (AA). Among all 767 patients 39 men, or 5.1 percent, developed metastases and among the 646 men who received definitive therapy (e.g., surgery, radiation, radiation and hormones) 28 men, or 4.3 percent, developed metastatic disease. The results showed that the Prolaris test was a significant predictor of metastatic disease with a nearly 3-fold increased risk for each one-unit increase on the Prolaris test score (Hazard Ratio per unit score = 2.76; P = 2.8x10-11). Importantly, there was no difference in predictive performance between races (p=0.20) or treatment groups (p=0.09). When combined with CAPRA the Prolaris test was highly predictive of metastatic disease (HR for combined clinical risk (CCR) = 3.86; p= 2.8x10-23). Contrary to expectations, this large study found no evidence that AA men have more aggressive prostate cancer than non-AA men after accounting for all molecular and clinical information.